Regeneron Pharmaceuticals Future Growth

Future criteria checks 1/6

Regeneron Pharmaceuticals is forecast to grow earnings and revenue by 7.9% and 7.2% per annum respectively. EPS is expected to grow by 8.2% per annum. Return on equity is forecast to be 14.7% in 3 years.

Key information

7.9%

Earnings growth rate

8.20%

EPS growth rate

Biotechs earnings growth	23.8%
Revenue growth rate	7.2%
Future return on equity	14.72%
Analyst coverage	Good
Last updated	26 Dec 2025

Recent future growth updates

Recent updates

Regeneron: The Turnaround Is Gaining Steam

Dec 20

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Nov 19

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think

Nov 09

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Feb 04

Regeneron: Phase III Success In Skin Cancer For Libtayo

Jan 15

Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025

Jan 05

Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025

Dec 06

Regeneron: The Biotech Stock To Buy Now

Nov 19

Earnings and Revenue Growth Forecasts

NasdaqGS:REGN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	16,634	4,892	4,993	5,974	21
12/31/2026	15,149	4,085	4,441	5,299	26
12/31/2025	14,212	4,288	5,064	5,544	27
9/30/2025	14,248	4,578	3,881	5,071	N/A
6/30/2025	14,214	4,459	3,556	4,744	N/A
3/31/2025	14,086	4,499	2,962	3,953	N/A
12/31/2024	14,202	4,413	3,539	4,421	N/A
9/30/2024	13,847	4,655	3,319	4,247	N/A
6/30/2024	13,489	4,322	3,184	4,071	N/A
3/31/2024	13,100	3,858	3,930	4,739	N/A
12/31/2023	13,117	3,954	3,668	4,594	N/A
9/30/2023	13,097	3,991	4,359	5,224	N/A
6/30/2023	12,671	4,299	3,004	4,739	N/A
3/31/2023	12,370	4,183	2,527	4,281	N/A
12/31/2022	12,173	4,338	3,398	5,015	N/A
9/30/2022	13,710	5,370	4,148	5,668	N/A
6/30/2022	14,227	5,687	7,869	8,452	N/A
3/31/2022	16,508	7,934	7,936	8,515	N/A
12/31/2021	16,072	8,075	6,529	7,081	N/A
9/30/2021	13,543	6,996	5,381	5,940	N/A
6/30/2021	12,384	6,205	1,694	2,272	N/A
3/31/2021	9,198	4,004	2,029	2,589	N/A
12/31/2020	8,497	3,513	2,004	2,618	N/A
9/30/2020	7,938	3,156	1,582	2,175	N/A
6/30/2020	7,387	2,984	2,425	2,986	N/A
3/31/2020	7,013	2,279	1,706	2,231	N/A
12/31/2019	6,558	2,116	2,000	2,430	N/A
9/30/2019	6,622	2,144	1,995	2,371	N/A
6/30/2019	6,542	2,069	N/A	2,267	N/A
3/31/2019	6,572	2,428	N/A	2,473	N/A
12/31/2018	5,146	2,444	N/A	2,195	N/A
9/30/2018	6,365	1,798	N/A	2,033	N/A
6/30/2018	6,203	1,591	N/A	1,995	N/A
3/31/2018	6,065	1,428	N/A	1,570	N/A
12/31/2017	5,872	1,199	N/A	1,307	N/A
9/30/2017	5,517	1,278	N/A	1,118	N/A
6/30/2017	5,236	1,155	N/A	1,354	N/A
3/31/2017	4,979	963	N/A	1,784	N/A
12/31/2016	4,860	896	N/A	1,486	N/A
9/30/2016	4,732	797	N/A	1,377	N/A
6/30/2016	4,649	743	N/A	1,619	N/A
3/31/2016	4,435	741	N/A	1,477	N/A
12/31/2015	4,104	636	N/A	1,331	N/A
9/30/2015	3,808	571	N/A	1,247	N/A
6/30/2015	3,396	444	N/A	519	N/A
3/31/2015	3,063	346	N/A	597	N/A
12/31/2014	2,820	338	N/A	752	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: REGN's forecast earnings growth (7.9% per year) is above the savings rate (3.3%).

Earnings vs Market: REGN's earnings (7.9% per year) are forecast to grow slower than the US market (16.2% per year).

High Growth Earnings: REGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: REGN's revenue (7.2% per year) is forecast to grow slower than the US market (10.7% per year).

High Growth Revenue: REGN's revenue (7.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: REGN's Return on Equity is forecast to be low in 3 years time (14.7%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/28 01:33
End of Day Share Price	2025/12/26 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 61 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Regeneron Pharmaceuticals Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 15%

Price target decreased by 7.4% to US$738

Price target decreased by 7.0% to US$797

Consensus EPS estimates fall by 15%

Price target decreased by 8.6% to US$808

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Regeneron: The Turnaround Is Gaining Steam

Alvotech and Teva Pharmaceuticals Reach a Settlement and License Agreement with Regeneron Pharmaceuticals Inc

Co-Founder exercised options and sold US$23m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Lynozyfic Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Executive VP exercised options and sold US$2.3m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals Announces FDA Approval Of EYLEA HD Injection 8 Mg For Treatment Of Macular Edema Following Retinal Vein Occlusion And Monthly Dosing Across Approved Indications

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc

Upcoming dividend of US$0.88 per share

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think

Regeneron Pharmaceuticals, Inc. Announces Detailed Positive Phase 2 Trial Results Evaluating Two Novel Investigational Factor Xi Antibodies - Regn7508cat and Regn9933a2

Insider exercised options and sold US$2.2m worth of stock

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on December 05, 2025

Consensus EPS estimates increase by 15%

Regeneron Pharmaceuticals, Inc. Announces European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion for Libtayo (Cemiplimab)

Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the PD-1 Inhibitor Libtayo(Cemiplimab-Rwlc) as an Adjuvant Treatment for Adult Patients

Regeneron Pharmaceuticals, Inc. to Report Q3, 2025 Results on Oct 28, 2025

U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi Announces That European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive CHMP Opinion

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva, Demonstrating That Garetosmab Prevents Greater Than 99% of Abnormal Bone Formation

Regeneron Pharmaceuticals, Inc. Announces Five-Year Follow-Up Results on Overall Survival from the Phase 3 Empower-Lung 3 Trial

Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals Announces FDA Review Extension for EYLEA HD® Prefilled Syringe and Expanded Indications

Upcoming dividend of US$0.88 per share

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Declares A Cash Dividend on the Common Stock and Class A Stock, Payable on September 3, 2025

Regeneron Pharmaceuticals, Inc. Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myelomac

Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Index

Regeneron Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 01, 2025

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Price target decreased by 7.4% to US$738

Regeneron Pharmaceuticals, Inc. Announces Interim Results from Ongoing Phase 2 Cloud Ridge Trial Confirm Potential to Improve the Quality of Semaglutide (Glp-1 Receptor Agonist)-Induced Weight Loss by Preserving Lean Mass

Investor sentiment deteriorates as stock falls 17%

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Regeneron Pharmaceuticals, Inc. Announces Initial Results from Two Cohorts of the Phase 1B Linker-Mm2 Trial Evaluating Linvoseltamab in Combination with Two Different Proteasome Inhibitors

Undisclosed acquirer proposed to acquire 23andMe Holding Co. (OTCPK:MEHC.Q) for approximately $260 million.

Upcoming dividend of US$0.88 per share

Price target decreased by 7.0% to US$797

Consensus EPS estimates fall by 15%

Regeneron Pharmaceuticals, Inc. Announces 24 Abstracts on Dupixent (Dupilumab) Clinical Data and Real-World Analyses in Respiratory Diseases

Price target decreased by 8.6% to US$808

Regeneron Pharmaceuticals, Inc. Declares Cash Dividend on the Common Stock and Class A Stock, Payable on June 6, 2025

First quarter 2025 earnings: EPS in line with expectations, revenues disappoint

Regeneron Pharmaceuticals, Inc. Announces Approval in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Provides Update on EYLEA HD®? (aflibercept) Injection 8 mg Supplemental Biologics License Application

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts EYLEA HD (aflibercept) Injection 8 mg

Biocon Biologics Ltd Announces Settlement and License Agreement with Regeneron

Regeneron: Still A Biotech Juggernaut

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2025

Dupixent And EYLEA Will Open New Therapeutic Frontiers

Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab)

Regeneron Pharmaceuticals, Inc. to Report Q1, 2025 Results on Apr 29, 2025

Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad

Linvoseltamab Recommends for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts odronextamab BLA for the Treatment of Relapsed/Refractory Follicular Lymphoma

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

U.S. Food and Drug Administration Accepts Linvoseltamab BLA for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces First Presentation of Positive Results from the Phase 3 QUASAR Trial

Full year 2024 earnings: EPS misses analyst expectations

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Regeneron Pharmaceuticals, Inc. Approves the Initiation of A Quarterly Cash Dividend Program and Declares A Cash Dividend, Payable on March 20, 2025

Regeneron: Phase III Success In Skin Cancer For Libtayo

Regeneron Pharmaceuticals, Inc. Announces Adjuvant Libtayo (Cemiplimab) Significantly Improves Disease-Free Survival After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 Trial